The modern therapeutic landscape is defined by an ever-growing portfolio of complex drug products – from biologics and gene therapies to mRNA-based vaccines and monoclonal antibodies. These therapies, which often involve intricate fomulations and require advanced sterile processing, have fundamentally altered the demands placed on fill-finish operations.
Frank Tagliaferri, chief scientific officer at Pace® Life Sciences, noted the ongoing growth driven by these advanced therapies. “The demand for fill-finish continues to grow due to the rising nmber of biologics and gene therapy products being developed, predominantly for parenteral administration,” he said. “The increasing introduction of more convenient and user-friendly routes of administration for these products, such as semaglutides, has also significantly contributed to the demand for more manufacturing capacity.”
Read the full article here.